Tags » Ribavirin

Sofosbuvir plus ribavirin is good for with HCV genotype 4 infection

CONCLUSION: The findings from the present study suggest that 24 weeks of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection. 360 more words


Boceprevir (BOC) prevents more HCV liver complications

CONCLUSION: Compared with SOC, BOC prevents more HCV liver complications from HCV genotype 1, particularly in patients who have failed previous SOC. Improved SVR and shortened duration of treatment result in BOC being potentially cost-saving or cost-effective in an Asian population. 317 more words


Why is there no broad spectrum antiviral for viruses like there are broad spectrum antibiotics?

Currently, why there are few broad-spectrum anti-viral drugs

  • The traditional anti-viral drug development blue-print focused on a specific virus.
  • The goal was to try to prevent one of the following from happening, virus attachment, internalization, fusion, nuclear import-export, replication, protein synthesis, release from infected cells.
  • 719 more words

Crimean Congo Haemorrhagic Fever - An Introduction

A graduate of the University of Texas Health Science Center in San Antonio, TX, and the founding director of Global NeuroCare, Dr. James C. Johnston strives to increase the effectiveness and accessibility of neurology care worldwide. 233 more words

Dr. James C Johnston

Bristol-Myers Squibb luncurkan Daklinza

September lalu Bristol-Myers Squibb meluncurkan Daklinza (Daclatasvir), sebuah antivirus HCV pertama yang menargetkan non-struktural 5A protein (NS5A) untuk mencegah replikasi virus dan perkembangan virion. Daklinza dapat di kombinasikan dengan sofosbuvir untuk pengobatan 12 minggu pada pasien dengan genotipe 1sampai dengan 4 tanpa indikasi sirosis, atau 24 minggu pada mereka yang memiiki sirosis hati Dan untuk pasien dengan infeksi genotipe 3 dapat berobat dengan daclatasvir dan sofosbuvir dikombinasi dengan ribavirin selama 24 minggu. 111 more words


Abbvie luncurkan dua jenis obat baru untuk hepatitis C

Abbvie di bulan Februari lalu telah mengumumkan peluncuran dua obat untuk perawatan Hepatitis C, Exviera (dasabuvir) dan Viekirax (ombitasvir/paritaprevir/ritonavir) keduanya diindikasikan untuk pengobatan infeksi hepatitis C kronis. 187 more words


Hepatitis C, new drugs on the horizon

A new generation of hepatitis C drugs have emerged that have higher sustained virologic response (SVR) — a measure of efficacy defined as the absence of detectable RNA of the hepatitis C virus in the blood — shorter and less complicated treatment protocols, and have similar safety profiles to current therapies that are based on peginterferon and/or ribavirin.  105 more words

Medical Communications